» Articles » PMID: 36862189

Pathomechanisms of Cognitive Impairment in Progressive Supranuclear Palsy

Overview
Specialties Neurology
Physiology
Date 2023 Mar 2
PMID 36862189
Authors
Affiliations
Soon will be listed here.
Abstract

Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by early postural instability and falls, oculomotor dysfunction (vertical supranuclear gaze palsy), parkinsonism with poor response to levodopa, pseudobulbar palsy, and cognitive impairment. This four-repeat tauopathy is morphologically featured by accumulation of tau protein in neurons and glia causing neuronal loss and gliosis in the extrapyramidal system associated with cortical atrophy and white matter lesions. Cognitive impairment being frequent in PSP and more severe than in multiple system atrophy and Parkinson disease, is dominated by executive dysfunction, with milder difficulties in memory, and visuo-spatial and naming dysfunctions. Showing longitudinal decline, it has been related to a variety of pathogenic mechanisms associated with the underlying neurodegenerative process, such as involvement of cholinergic and muscarinergic dysfunctions, and striking tau pathology in frontal and temporal cortical regions associated with reduced synaptic density. Altered striatofrontal, fronto-cerebellar, parahippocampal, and multiple subcortical structures, as well as widespread white matter lesions causing extensive connectivity disruptions in cortico-subcortical and cortico-brainstem connections, support the concept that PSP is a brain network disruption disorder. The pathophysiology and pathogenesis of cognitive impairment in PSP, as in other degenerative movement disorders, are complex and deserve further elucidation as a basis for adequate treatment to improve the quality of life of patients with this fatal disease.

Citing Articles

The Spectrum of Cognitive Impairment in Atypical Parkinsonism Syndromes: A Comprehensive Review of Current Understanding and Research.

Jellinger K Diseases. 2025; 13(2).

PMID: 39997046 PMC: 11854393. DOI: 10.3390/diseases13020039.


Resting-State Functional MRI Approaches to Parkinsonisms and Related Dementia.

Piramide N, De Micco R, Siciliano M, Silvestro M, Tessitore A Curr Neurol Neurosci Rep. 2024; 24(10):461-477.

PMID: 39046642 PMC: 11415422. DOI: 10.1007/s11910-024-01365-8.


Levodopa modulates semantic fluency and uniqueness in non-demented patients with progressive supranuclear palsy.

Ma J, Zhang G, Zhao Z, Chan P, Ye Z Brain Behav. 2024; 14(7):e3606.

PMID: 38945805 PMC: 11214872. DOI: 10.1002/brb3.3606.


Pathomechanisms of cognitive and behavioral impairment in corticobasal degeneration.

Jellinger K J Neural Transm (Vienna). 2023; 130(12):1509-1522.

PMID: 37659990 DOI: 10.1007/s00702-023-02691-w.

References
1.
Abos A, Segura B, Baggio H, Campabadal A, Uribe C, Garrido A . Disrupted structural connectivity of fronto-deep gray matter pathways in progressive supranuclear palsy. Neuroimage Clin. 2019; 23:101899. PMC: 6593210. DOI: 10.1016/j.nicl.2019.101899. View

2.
Bakar Z, Kato T, Yanagisawa D, Bellier J, Mukaisho K, Tooyama I . Immunohistochemical Study of Mitochondrial Ferritin in the Midbrain of Patients with Progressive Supranuclear Palsy. Acta Histochem Cytochem. 2021; 54(3):97-104. PMC: 8275861. DOI: 10.1267/ahc.21-00019. View

3.
Bakar Z, Bellier J, Yanagisawa D, Kato T, Mukaisho K, Tooyama I . LC3/FtMt Colocalization Patterns Reveal the Progression of FtMt Accumulation in Nigral Neurons of Patients with Progressive Supranuclear Palsy. Int J Mol Sci. 2022; 23(1). PMC: 8745681. DOI: 10.3390/ijms23010537. View

4.
Adams N, Jafarian A, Perry A, Rouse M, Shaw A, Murley A . Neurophysiological consequences of synapse loss in progressive supranuclear palsy. Brain. 2022; 146(6):2584-2594. PMC: 10232290. DOI: 10.1093/brain/awac471. View

5.
Aghakhanyan G, Rullmann M, Rumpf J, Schroeter M, Scherlach C, Patt M . Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [F]PI-2620 PET/MRI study. Eur J Nucl Med Mol Imaging. 2022; 50(1):103-114. DOI: 10.1007/s00259-022-05952-0. View